SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

GlaxoSmithKline Pharmaceuticals rises on establishing Omnichannel Team

08 Dec 2023 Evaluate

Glaxosmithkline Pharmaceuticals is currently trading at Rs. 1695.40, up by 5.95 points or 0.35% from its previous closing of Rs. 1689.45 on the BSE.

The scrip opened at Rs. 1690.15 and has touched a high and low of Rs. 1710.00 and Rs. 1690.15 respectively. So far 1655 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1739.60 on 04-Dec-2023 and a 52 week low of Rs. 1228.00 on 03-May-2023.

Last one week high and low of the scrip stood at Rs. 1739.60 and Rs. 1671.00 respectively. The current market cap of the company is Rs. 28721.10 crore.

The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 12.52% and 12.49% respectively.

GlaxoSmithKline Pharmaceuticals has established an Omnichannel Team to expand its reach and coverage to the target segments by leveraging technology and improve productivity. Continuing its focus on improving operating efficiencies, the company has also completed the Voluntary Retirement Scheme (VRS) (for Commercial function employees in Field Sales and HO) and spent a sum of Rs 156.57 crore as the one-off cost of the VRS.

GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Glaxosmithkline Phar Share Price

2447.85 28.75 (1.19%)
17-Apr-2026 10:02 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1688.60
Dr. Reddys Lab 1221.90
Cipla 1234.15
Zydus Lifesciences 942.95
Lupin 2322.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×